FDA's May 2026 GLP-1 compounding letter: what it actually changes

What did @betterlivingforeveryone actually say?

Tiffany, a PA who describes herself as a GLP-1 advocate, argued that recent headlines about the FDA removing semaglutide and tirzepatide from a bulk compounding list are non-news. Her core claim: these drugs were never formally on that list to begin with, so the FDA's May 2026 letter changes nothing for patients. She says 503B pharmacies lost the right to compound GLP-1s when the shortage ended in March 2025, and that 503A pharmacies, regulated at the state level, can still make personalized compounded versions today.

She also named two major 503B pharmacies, ProRx and BPI, as having recently stopped production, framing that as a separate development from the FDA letter. Her takeaway: "take a breath. It's going to be okay."

This is a nuanced regulatory argument, not a simple health claim, which makes it harder to fact-check than typical TikTok medical content. But nuanced does not mean correct.

Does the science and regulatory record back this up?

Mostly, yes, with some important gaps. The 503B versus 503A framework she describes is real and the distinction matters. Under the Drug Quality and Security Act, 503B outsourcing facilities operate under FDA oversight and may compound drugs that appear on the FDA's drug shortage list. Once FDA declared the semaglutide and tirzepatide shortages resolved in early 2025, the legal basis for 503B compounding of those specific drugs collapsed.

The FDA's enforcement discretion policies and subsequent guidance from late 2024 and early 2025 are consistent with what she describes. The agency gave 503Bs a wind-down window, not an indefinite runway. The FDA's position on bulk substance nominations is also accurate: both semaglutide and tirzepatide were nominated to the 503B bulks list but never formally approved onto it. The Pharmacy Compounding Advisory Committee reviewed semaglutide in 2024 and did not recommend its addition.

Where her framing gets shaky is on 503A pharmacies. She says they are not overseen by the federal government, which is an oversimplification. The FDA does have authority over 503A pharmacies under certain circumstances, including when drugs are compounded in ways that resemble manufacturing, and the agency has taken enforcement actions against 503A compounders before.

What did they get wrong, or right?

She got the structural regulatory argument right. The shortage-based pathway was always temporary, and the bulk substance pathway was never the mechanism 503Bs used for GLP-1s. Calling the May 2026 letter "old news" is defensible if that letter is, as she suggests, simply formalizing what was already the legal status quo.

However, three things deserve pushback. First, her claim that 503A pharmacies operate completely outside federal jurisdiction is inaccurate. The FDA has authority over 503A compounders when they engage in practices that look like manufacturing, distribute inordinate amounts to out-of-state patients, or compound drugs that are not patient-specific. Second, she says compounded GLP-1s are fine as long as they are "not an exact copy," but FDA guidance on this is more complicated. The agency has questioned whether adding ingredients like B12 or glycine is enough to differentiate a compound, and enforcement actions have targeted some of these combinations. Third, she does not mention that compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality, which is not a minor footnote for patients making medication decisions.

What should you actually know?

If you are currently getting compounded semaglutide or tirzepatide, here is the honest picture. The 503B channel for these drugs is effectively closed, and two of the largest producers have stopped. The 503A channel remains open in most states, but it is not a uniformly regulated, guaranteed-safe alternative. Quality and sterility standards vary by pharmacy and state board. A 2023 analysis by Downing et al. in the New England Journal of Medicine documented serious adverse events, including hospitalizations, linked to compounded GLP-1 products, many tied to dosing errors and formulation inconsistencies.

The FDA has also issued warning letters to specific 503A compounders, so the idea that state regulation alone is sufficient consumer protection is worth scrutinizing. If you are considering a compounded GLP-1, asking your prescriber about pharmacy accreditation, third-party testing, and state board standing is reasonable due diligence, not fear-mongering.

Tiffany's overall message, that the May 2026 FDA letter is not a new shutdown, appears to be directionally accurate based on what we know about the regulatory timeline. But the reassurance that "nothing has changed" skips over the fact that the access situation for patients has materially changed since early 2025, and that accessing compounded GLP-1s today carries regulatory and quality uncertainty that was not present during the shortage window.